Equipes : Equipe Épidémiologie clinique, Prévention, Qualité de Vie – Recherche clinique en oncologie

June 26, 2009

Rechercher dans dbCGE
S’identifier

flag_fr-5969932 flag_uk-3875373 bandeau-annuaire-3938434

2008/11/04 – Post-Doctoral position in Picosecond Ultrasonics in a single cell: PicoBio – The candidate will have extensive hands- (La suite)

2009/11/19 – 3è Forum du CGE (Château de l’Ile, Strasbourg) – Le Cancéropôle du Grand-Est organise la 3è édition de son Forum Il (La suite)

Intitulé

Épidémiologie clinique, Prévention, Qualité de Vie – Recherche clinique en oncologie

Responsable d’équipe

Affiliation(s)

Membres de l’équipe

Thierry CONROY

Axes CGE

1 : Indicateurs de santé et évaluation des pratiques en cancérologie

Thèmes Cancer

Essais cliniques de phase II et phase IIIUtilisation de la qualité de vie comme critère de jugement

Développement de questionnaires de qualité de vie spécifiques de cancer

Projets

	2004 – QDV-COLON (porteur : Thierry CONROY) Validation de questionnaires de qualité de vie pour les patients atteints de cancers colorectaux. Comparaison de ces questionnaires : QLQ-C30 – QLQ-CR38 de l’EORTC et FACT-C
	2004 – RESPONSESHIFT (porteur : Franck Bonnetain) Qualité de vie, « response shift » et attentes de santé : analyse longitudinale chez les patientes ayant un cancer du sein

Projets hors INCa

2004 – PHRC – Phase II-III irinotecan, oxaliplatine, 5-FU et acide folinique (Folfirinox) versus gemcitabine dans les cancers du pancréas métastatiques (FNCLCC Accord 11)

Collaborations

EORTC gastrointestinal group, Bruxelles (B)
EORTC Quality of life group, Bruxelles (B)

Publications

	Conroy T. [Clinical case: Should esophageal cancers still be operated on?] Gastroenterol Clin Biol. 2009 Mar 20.
	Blazeby JM, Fayers P, Conroy T, Sezer O, Ramage J, Rees M. Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. Br J Surg. 2009 Mar;96(3):291-8.
	Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouche O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009 Apr;20(4):674-80. Epub 2009 Jan 29.
	Adenis A, Conroy T. Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer. J Clin Oncol. 2009 Jan 20;27(3):467-8; author reply 468-9. Epub 2008 Dec
	Adenis A, Mariette C, Mirabel X, Seitz JF, Conroy T. Cetuximab with concurrent chemoradiation for esophagogastric cancer: in regard to Safran et al. (Int J Radiat Oncol Biol Phys 2008;70:391-395). Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):958-9.
	Conroy T, Viret F, Francois E, Seitz JF, Boige V, Ducreux M, Ychou M, Metges JP, Giovannini M, Yataghene Y, Peiffert D. Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. Br J Cancer. 2008 Nov 4;99(9):1395-401. Epub 2008 Oct 7.
	Becouarn Y, Guillo S, Artru P, Assenat E, Bosset JF, Conroy T, Francois E, Taieb J, Touboul E. [Systematic review: value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)] Bull Cancer. 2008 Aug;95(7):717-34. Review
	Hebbar M, Di Fiore F, Conroy T, Giraud C, Gasnault L, Fournier C, Pereira R, Bouche O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. Oncology. 2007;73(3-4):185-91. Epub 2008 Apr 16.
	Burtin P, Bouche O, Giovannini M, Pelletier M, Conroy T, Ruget O, Arsene D, Milan C, Bedenne L. Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Federation Francophone de Cancerologie Digestive. Gastroenterol Clin Biol. 2008 Mar;32(3):213-20. Epub 2008 Mar 26.
	Rotonda C, Conroy T, Mercier M, Bonnetain F, Uwer L, Miny J, Montcuquet P, Leonard I, Adenis A, Breysacher G, Guillemin F. Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C. Qual Life Res. 2008 Apr;17(3):437-45. Epub 2008 Mar 13.
	Byrne C, Griffin A, Blazeby J, Conroy T, Efficace F. Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer. Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S95-104. Epub 2007 Nov 26.
	Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8.
	Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006 Oct 1;24(28):4620-5.
	Bonnetain F, Bouche O, Michel P, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Paillot B, Arveux P, Milan C, Bedenne L. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol. 2006 May;17(5):827-34. Epub 2006 Mar 8.
	Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul JL, Giovannini M, Etienne PL, Mitry E, Seitz JF, Rougier P, Girault C, Bedenne L. Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. Gastroenterol Clin Biol. 2005 Nov;29(11):1113-24.
	Lejeune C, Bismuth MJ, Conroy T, Zanni C, Bey P, Bedenne L, Faivre J, Arveux P, Guillemin F. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med. 2005 Dec;46(12):2020-8.
	Bredart A, Mignot V, Rousseau A, Dolbeault S, Beauloye N, Adam V, Elie C, Leonard I, Asselain B, Conroy T. [Cancer patient’s satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response] Rev Epidemiol Sante Publique. 2005 Sep;53 Spec No 1:1S31-8.
	Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer–a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005 Feb 20;23(6):1228-36.
	Conroy T, Mercier M, Bonneterre J, Luporsi E, Lefebvre JL, Lapeyre M, Puyraveau M, Schraub S. French version of FACT-G: validation and comparison with other cancer-specific instruments. Eur J Cancer. 2004 Oct;40(15):2243-52.
	Bredart A, Mignot V, Rousseau A, Dolbeault S, Beauloye N, Adam V, Elie C, Leonard I, Asselain B, Conroy T. Validation of the EORTC QLQ-SAT32 cancer inpatient satisfaction questionnaire by self- versus interview-assessment comparison. Patient Educ Couns. 2004 Aug;54(2):207-12.
	Rauch P, Miny J, Conroy T, Neyton L, Guillemin F. Quality of life among disease-free survivors of rectal cancer. J Clin Oncol. 2004 Jan 15;22(2):354-60.
	Pourel N, Peiffert D, Lartigau E, Desandes E, Luporsi E, Conroy T. Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):742-51.
	Peiffert D, Giovannini M, Ducreux M, Michel P, Francois E, Lemanski C, Mirabel X, Cvitkovic F, Luporsi E, Conroy T, Gerard JP. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol. 2001 Mar;12(3):397-404.
	Bonnetain F, Bedenne L, Michel P, Bouche O, Triboulet JP, Conroy T, Pezet D, Roullet B, Milan C, Arveux P, FFCD. Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs radiochemotherapy in patients with locally advanced esophageal cancer). Proc Am Soc Clin Oncol 22: page 250, 2003 (abstr 1002)
	Bonnetain F, Bouche O, Raoul J, Giovannini M, Etienne P, Bedenne L, Seitz J, Lledo G, Conroy T, Arveux P. Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA). Proc Am Soc Clin Oncol 23, 2004.
	Desandes E, Conroy T, Briancon S, Guillemin F, Empereur F, Guillemin F, Léonard I, Bey P. Impact de la qualité de vie sur la satisfaction des soins reçus chez les patients hospitalisés ayant un cancer. Rev Epidemiol Santé Publique 2000; 48: 3S81.

Crédits
Liens
Plan du site
Contact

La visualisation de ces pages est meilleure avec des navigateurs respectant les standards (par exemple Mozilla).